Helena A. Yu

16.8k total citations · 7 hit papers
195 papers, 8.4k citations indexed

About

Helena A. Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Helena A. Yu has authored 195 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Pulmonary and Respiratory Medicine, 146 papers in Oncology and 42 papers in Molecular Biology. Recurrent topics in Helena A. Yu's work include Lung Cancer Treatments and Mutations (174 papers), Lung Cancer Research Studies (70 papers) and Colorectal Cancer Treatments and Studies (57 papers). Helena A. Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (174 papers), Lung Cancer Research Studies (70 papers) and Colorectal Cancer Treatments and Studies (57 papers). Helena A. Yu collaborates with scholars based in United States, South Korea and Japan. Helena A. Yu's co-authors include Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, William Pao, Vincent A. Miller, Maureen F. Zakowski and Charles M. Rudin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Helena A. Yu

180 papers receiving 8.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

2013 1.9k citations Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research profile →
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →
Lineage plasticity in cancer: a shared pathway of therapeutic resistance

2020 310 citations Helena A. Yu, Charles M. Rudin et al. profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Geoffrey R. Oxnard, Helena A. Yu et al. Annals of Oncology profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Lecia V. Sequist, Ji‐Youn Han et al. profile →
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

2019 271 citations Adam J. Schoenfeld, Kathryn C. Arbour et al. Annals of Oncology profile →
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Helena A. Yu

Since Specialization

Citations

This map shows the geographic impact of Helena A. Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena A. Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena A. Yu more than expected).

Fields of papers citing papers by Helena A. Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena A. Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena A. Yu. The network helps show where Helena A. Yu may publish in the future.

Co-authorship network of co-authors of Helena A. Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Helena A. Yu. A scholar is included among the top collaborators of Helena A. Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena A. Yu. Helena A. Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), Yi‐Long Wu, (unknown), Junko Tanizaki, (unknown), (unknown), Xiaohan Shi, Toon van der Gronde, Helena A. Yu, (unknown)	1
2	Management of EGFR-Variant and ALK-Positive Non–Small Cell Lung Cancer Brain Metastasis 2025 ·JAMA Oncology ·Luke Pike, Helena A. Yu, Chad G. Rusthoven	0
3	Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases 2025 ·Annals of Oncology ·James A. Wilcox, (unknown), (unknown), (unknown), (unknown), Glenn Heller, Noura J. Choudhury, Jeff Ross, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Mark T.A. Donoghue, Adrienne Boire, Helena A. Yu	0
4	ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib 2025 ·JCO Precision Oncology ·Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Y. Lau, Helena A. Yu	4
5	Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer Treated With Osimertinib 2025 ·JCO Precision Oncology ·Monica F. Chen, (unknown), Jennifer Ma, (unknown), (unknown), (unknown), Mark G. Kris, James Huang, Harini Veeraraghavan, Daniel R. Gomez, Helena A. Yu	1
6	REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations. 2024 ·Journal of Clinical Oncology ·Helena A. Yu, Benjamin Besse, (unknown), Ying Cheng, Wei Li, Volker Wacheck, John V. Heymach	2
7	A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease. 2024 ·Journal of Clinical Oncology ·Helena A. Yu, Monica F. Chen, Angela Bik‐Yu Hui, Noura J. Choudhury, Jake June-Koo Lee, (unknown), Linda S. Ahn, (unknown), Monica Nesselbush, (unknown), Glenn Heller, Kathryn C. Arbour, Fernando C. Santini, Michael Offin, Jamie E. Chaft, Robert J. Young, Gregory J. Riely, Mark G. Kris, Maximilian Diehn, Adrienne Boire	6
8	Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas 2023 ·Clinical Cancer Research ·Arielle Elkrief, Alex Makhnin, (unknown), Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu	1
9	Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis 2023 ·Nature Communications ·Anna Skakodub, Henry Walch, Kathryn R. Tringale, (unknown), Brandon S. Imber, Harish N. Vasudevan, Bob T. Li, Nelson S. Moss, Kenny Kwok Hei Yu, Boris Mueller, Simon N. Powell, Pedram Razavi, Helena A. Yu, Jorge S. Reis‐Filho, Daniel R. Gomez, Nikolaus Schultz, Luke Pike	28
10	Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers 2023 ·Clinical Cancer Research ·Julia Rotow, Jyoti D. Patel, (unknown), Helena A. Yu, Mark M. Awad, Jonathan W. Goldman, Hovav Nechushtan, Matthias Scheffler, Chih‐Hsi S. Kuo, Senthil Rajappa, Guilherme Harada, (unknown), (unknown), (unknown), Rebecca Tupper, Geoffrey R. Oxnard, Jennifer Kherani, Alexander Drilon	26
11	Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON breakdown → 2022 ·Cancer Discovery ·Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Lecia V. Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena A. Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, С. В. Орлов, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne	95
12	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells 2022 ·Science Translational Medicine ·Moiez Ali, Min Lu, (unknown), Ryan S. Soderquist, Christine E. Eyler, (unknown), Carolyn Glass, Christopher F. Bassil, (unknown), D. Lucas Kerr, Christina J. Falcon, Helena A. Yu, Aaron N. Hata, Collin M. Blakely, Caroline E. McCoach, Trever G. Bivona, Kris C. Wood	29
13	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions 2021 ·Clinical Cancer Research ·Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely	47
14	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer 2021 ·Clinical Cancer Research ·Kathryn C. Arbour, Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knežević, Glenn Heller, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Charles M. Rudin, Piro Lito, Gregory J. Riely	82
15	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Helena A. Yu, Luis Paz‐Ares, James Chih‐Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard	31
16	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers 2018 ·Clinical Cancer Research ·Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann	230
17	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance 2018 ·Clinical Cancer Research ·Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Hyunjae R. Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi	188
18	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Kathryn C. Arbour, (unknown), Hyunjae R. Kim, Jordan Dienstag, Helena A. Yu, Francisco Sánchez-Vega, Piro Lito, Michael F. Berger, David B. Solit, Matthew D. Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely	317
19	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations 2017 ·Clinical Cancer Research ·Helena A. Yu, Alexander I. Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey L. Evans, Ronan J. Kelly, (unknown), Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, (unknown), Anne Keating, Geoffrey R. Oxnard	23
20	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping breakdown → 2015 ·Cancer Discovery ·Paul K. Paik, Alexander Drilon, Pang‐Dian Fan, Helena A. Yu, Natasha Rekhtman, Michelle S. Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F. Berger, Charles M. Rudin, Marc Ladanyi	423

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact